Literature DB >> 30012421

Peroxisomes and cancer: The role of a metabolic specialist in a disease of aberrant metabolism.

Michael S Dahabieh1, Erminia Di Pietro2, Maïka Jangal1, Christophe Goncalves3, Michael Witcher1, Nancy E Braverman4, Sonia V Del Rincón5.   

Abstract

Cancer is irrevocably linked to aberrant metabolic processes. While once considered a vestigial organelle, we now know that peroxisomes play a central role in the metabolism of reactive oxygen species, bile acids, ether phospholipids (e.g. plasmalogens), very-long chain, and branched-chain fatty acids. Immune system evasion is a hallmark of cancer, and peroxisomes have an emerging role in the regulation of cellular immune responses. Investigations of individual peroxisome proteins and metabolites support their pro-tumorigenic functions. However, a significant knowledge gap remains regarding how individual functions of proteins and metabolites of the peroxisome orchestrate its potential role as a pro-tumorigenic organelle. This review highlights new advances in our understanding of biogenesis, enzymatic functions, and autophagic degradation of peroxisomes (pexophagy), and provides evidence linking these activities to tumorigenesis. Finally, we propose avenues that may be exploited to target peroxisome-related processes as a mode of combatting cancer.
Copyright © 2018 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Cancer; Metabolism; Mitochondrion; Peroxisome; Pexophagy; Plasmalogen

Mesh:

Substances:

Year:  2018        PMID: 30012421     DOI: 10.1016/j.bbcan.2018.07.004

Source DB:  PubMed          Journal:  Biochim Biophys Acta Rev Cancer        ISSN: 0304-419X            Impact factor:   10.680


  24 in total

1.  PI5P4Ks drive metabolic homeostasis through peroxisome-mitochondria interplay.

Authors:  Archna Ravi; Lavinia Palamiuc; Ryan M Loughran; Joanna Triscott; Gurpreet K Arora; Avi Kumar; Vivian Tieu; Chantal Pauli; Matthias Reist; Rachel J Lew; Shauna L Houlihan; Christof Fellmann; Christian Metallo; Mark A Rubin; Brooke M Emerling
Journal:  Dev Cell       Date:  2021-05-12       Impact factor: 13.417

Review 2.  Targeting the Redox Landscape in Cancer Therapy.

Authors:  Dilip Narayanan; Sana Ma; Dennis Özcelik
Journal:  Cancers (Basel)       Date:  2020-06-27       Impact factor: 6.639

3.  USP30: protector of peroxisomes and mitochondria.

Authors:  Victoria Riccio; G Angus McQuibban; Peter Kijun Kim
Journal:  Mol Cell Oncol       Date:  2019-04-16

Review 4.  Peroxisomes in Immune Response and Inflammation.

Authors:  Francesca Di Cara; Pierre Andreoletti; Doriane Trompier; Anne Vejux; Margret H Bülow; Julia Sellin; Gérard Lizard; Mustapha Cherkaoui-Malki; Stéphane Savary
Journal:  Int J Mol Sci       Date:  2019-08-08       Impact factor: 5.923

5.  ACOX1 destabilizes p73 to suppress intrinsic apoptosis pathway and regulates sensitivity to doxorubicin in lymphoma cells.

Authors:  Fei-Meng Zheng; Wang-Bing Chen; Tao Qin; Li-Na Lv; Bi Feng; Yan-Ling Lu; Zuo-Quan Li; Xiao-Chao Wang; Li-Ju Tao; Hong-Wen Li; Shu-You Li
Journal:  BMB Rep       Date:  2019-09       Impact factor: 4.778

Review 6.  Mechanisms and Functions of Pexophagy in Mammalian Cells.

Authors:  Jing Li; Wei Wang
Journal:  Cells       Date:  2021-05-03       Impact factor: 6.600

7.  Silencing PEX26 as an unconventional mode to kill drug-resistant cancer cells and forestall drug resistance.

Authors:  Michael S Dahabieh; Fan Huang; Christophe Goncalves; Raúl Ernesto Flores González; Sathyen Prabhu; Alicia Bolt; Erminia Di Pietro; Elie Khoury; John Heath; Zi Yi Xu; Joelle Rémy-Sarrazin; Koren K Mann; Alexandre Orthwein; François-Michel Boisvert; Nancy Braverman; Wilson H Miller; Sonia V Del Rincón
Journal:  Autophagy       Date:  2021-06-21       Impact factor: 13.391

Review 8.  Divide et Impera: Drp1-mediated Mitochondrial Fission in Glioma Malignancy.

Authors:  Dianelena Eugenio-Pérez; Alfredo Briones-Herrera; Elena Martínez-Klimova; José Pedraza-Chaverri
Journal:  Yale J Biol Med       Date:  2019-09-20

9.  HSD17B4, ACAA1, and PXMP4 in Peroxisome Pathway Are Down-Regulated and Have Clinical Significance in Non-small Cell Lung Cancer.

Authors:  Xiuzhi Zhang; Hongmei Yang; Jinzhong Zhang; Fenglan Gao; Liping Dai
Journal:  Front Genet       Date:  2020-03-20       Impact factor: 4.599

10.  PEX5, a novel target of microRNA-31-5p, increases radioresistance in hepatocellular carcinoma by activating Wnt/β-catenin signaling and homologous recombination.

Authors:  Jie Wen; Kai Xiong; Abudureyimujiang Aili; Hao Wang; Yuequan Zhu; Zhengquan Yu; Xueyan Yao; Ping Jiang; Lixiang Xue; Junjie Wang
Journal:  Theranostics       Date:  2020-04-06       Impact factor: 11.556

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.